

# Notice to the Annual General Meeting in Magle Chemoswed Holding AB (publ)

**The shareholders of Magle Chemoswed Holding AB (publ), org. no. 556913-4710 (the "Company"), are hereby invited to the Annual General Meeting (the "AGM") on 30 June 2026, at 15:00 CEST at the Company's premises at Agneslundsvägen 20B in Malmö, Sweden. The registration for the AGM starts at 14:30 CEST.**

## Right to participate

Shareholders who wish to participate in the AGM must:

- i. be entered in the register of shareholders maintained by Euroclear Sweden AB by 22 June 2026; and
- ii. no later than 24 June 2026, give notice of participation to the Company either by post to Magle Chemoswed Holding AB (publ), Agneslundsvägen 27, 212 15 Malmö, Sweden or via e-mail to [stamman@maglechemoswed.com](mailto:stamman@maglechemoswed.com). When providing such notice, the shareholder shall state name, personal or corporate registration number, address, telephone number, and the number of any accompanying assistants (not more than two), as well as information about any proxy.

If a shareholder is represented by proxy, a written, dated proxy for the representative must be issued. A proxy form is available on the Company's website, [www.maglegroup.com](http://www.maglegroup.com). If the proxy is issued by a legal entity, a certificate of registration or equivalent certificate of authority should be enclosed. To facilitate the registration at the AGM, the proxy and the certificate of registration or equivalent certificate of authority should be sent to the Company at the address set out above so that it is received by the Company no later than 24 June 2026.

## Nominee-registered shares

In order to be entitled to participate in the meeting, shareholders who have registered their shares in the name of a nominee must, in addition to announcing their intention to participate in the meeting, request that their shares be registered in their own name, so the shareholder is entered into the register of shareholders by 22 June 2026. This registration may be temporary (so-called voting right registration) and is requested by the nominee in accordance with the nominee's procedures and in advance as determined by the nominee. Voting right registrations completed no later than the second bank day after 22 June 2026 are considered when preparing the register of shareholders.

## Proposed agenda

1. Opening of the AGM
2. Election of Chairman of the AGM
3. Preparation and approval of the voting list
4. Approval of the agenda
5. Election of one or two persons to verify the minutes

6. The determination as to whether the AGM has been duly convened
7. Presentation of the annual report and auditor's report as well as the consolidated annual report and consolidated auditor's report
8. Resolutions on:
  - a. adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet;
  - b. dispositions regarding the Company's result according to the adopted balance sheet; and
  - c. discharge from liability for the members of the board of directors and the CEO.
9. Determination of the number of board members and auditors
10. Election of board of directors, chairman of the board and auditor
11. Determination of remuneration to be paid to the board of directors and auditor
12. Resolution on amendment of the articles of association
13. Resolution to authorise the board of directors to resolve on issues of shares, warrants and/or convertible debentures
14. Closing of the AGM

## **BOARD OF DIRECTORS' PROPOSED RESOLUTIONS**

### **Item 8 b): Resolution on dispositions regarding the Company's result according to the adopted balance sheet**

The board of directors proposes that no dividend be paid for the financial year 2025 and that the result for the year be carried forward.

### **Item 12: Resolution on amendment of the articles of association**

The board of directors proposes that the AGM, for the purpose of achieving appropriate limits for the number of shares and share capital, resolves to amend Section 4 of the articles of association as follows:

*Proposed wording of Section 4:*

The share capital shall amount to not less than SEK 1,500,000 and not more than SEK 6,000,000. The number of shares in the Company shall be not less than 30,000,000 and not more than 120,000,000.

The board of directors or the CEO shall be authorised to make such minor adjustments to this resolution as may be necessary in connection with registration with the Swedish Companies Registration Office.

*Majority requirements*

A valid resolution on item 12 requires the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the AGM.

### **Item 13: Resolution to authorise the board of directors to resolve on issues of shares, warrants and/or convertible debentures**

The board of directors proposes that the AGM authorises the board of directors to, on one or several occasions during the period up until the next annual general meeting, resolve to increase the Company's share capital through the issuance of shares, warrants and/or convertible debentures. The board of directors shall be able to resolve on the issuance of shares, warrants and /or convertible debentures with or without deviation from the shareholders' pre-emptive rights and /or with or without provisions concerning payment in kind, set-off, or other provisions specified in Chapter 13, Section 5, first paragraph, 6, Chapter 14, Section 5, first paragraph, 6, and Chapter 15, Section 5, first paragraph, 4, of the Swedish Companies Act.

Issuances in accordance with this authorisation shall be on market terms, subject to a market discount where applicable. The board of directors shall have the right to determine the terms and conditions for issuances in accordance with this authorisation and who shall have the right to subscribe for the shares, warrants and/or convertible debentures. The reason for why the board of directors shall be able to resolve on issuances with deviation from the shareholder's pre-emptive rights and/or with provisions concerning payment in kind, set-off, or other provisions is (i) that the Company should be able to issue shares, warrants and/or convertibles in connection with the acquisition of companies or operations, as well as (ii) being able to carry out directed issues with the aim of acquiring capital for the Company.

The board of directors is proposed to be authorised to make the minor adjustments in this resolution that may be necessary in connection with registration with the Swedish Companies Registration Office or other formal requirements.

#### *Majority requirements*

A valid resolution on item 13 requires the support of shareholders representing at least two-thirds of both the votes cast and the shares represented at the AGM.

#### **Shareholders' right to obtain information**

Shareholders are reminded of their right to, at the AGM, obtain information from the board of directors and the CEO in accordance with Chapter 7, Section 32 of the Swedish Companies Act.

#### **Available documentation**

Documents in accordance with the Swedish Companies Act will be available at the Company and on the Company's website, [www.maglegroup.com](http://www.maglegroup.com). The documents will also be sent to shareholders who so request and state their postal address.

#### **Processing of personal data**

For information about the processing of your personal data, it is referred to the privacy notice available at Euroclear's webpage.

Magle Chemoswed Holding AB (publ)'s corporate registration number is 556913-4710 and its registered office is in Malmö, Sweden.

Malmö in May 2026  
**Magle Chemoswed Holding AB (publ)**  
*The board of directors*

## Contacts

---

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

## About Us

---

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on [www.maglechemoswed.com](http://www.maglechemoswed.com) and [www.maglegroup.com](http://www.maglegroup.com) and [www.maglepharmaceut.com](http://www.maglepharmaceut.com) and [www.maglebiopolymers.com](http://www.maglebiopolymers.com)  
Redeye Nordic Growth AB is the company's Certified Adviser.

## Attachments

---

[Notice to the Annual General Meeting in Magle Chemoswed Holding AB \(publ\)](#)